A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Status:
Recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or
refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1
inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator,
have no other meaningful life-prolonging therapy options available.
ELU001 is a new chemical entity described as a C'Dot drug conjugate (CDC), consisting of
payloads (exatecans) and targeting moieties (folic acid analogs) covalently bound by linkers
to the C'Dot particle carrier. ELU001 will be the first drug-conjugate of its kind to be
introduced into the clinic, a first in class, and a novel molecular entity.